Aberdeen Group plc Decreases Stake in DaVita Inc. $DVA

Aberdeen Group plc reduced its stake in shares of DaVita Inc. (NYSE:DVA) by 76.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,546 shares of the company’s stock after selling 37,663 shares during the period. Aberdeen Group plc’s holdings in DaVita were worth $1,508,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. NewEdge Advisors LLC increased its holdings in shares of DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after purchasing an additional 88 shares during the period. Goldman Sachs Group Inc. boosted its position in DaVita by 19.1% in the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after buying an additional 28,739 shares during the last quarter. DekaBank Deutsche Girozentrale increased its holdings in DaVita by 8.4% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 14,013 shares of the company’s stock worth $1,991,000 after buying an additional 1,084 shares during the period. Ethic Inc. raised its position in DaVita by 36.9% during the 2nd quarter. Ethic Inc. now owns 3,091 shares of the company’s stock worth $438,000 after buying an additional 833 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its stake in DaVita by 4.0% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 113,503 shares of the company’s stock valued at $16,169,000 after acquiring an additional 4,404 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Stock Performance

Shares of DVA stock opened at $150.89 on Friday. The stock’s fifty day moving average is $120.72 and its two-hundred day moving average is $125.17. The firm has a market capitalization of $10.08 billion, a P/E ratio of 15.23, a PEG ratio of 0.53 and a beta of 0.99. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $157.12.

DaVita (NYSE:DVA) last released its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The company had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same quarter in the previous year, the company posted $2.24 earnings per share. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, equities analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on DVA shares. Barclays increased their price target on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 3rd. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Truist Financial set a $158.00 target price on shares of DaVita in a research note on Thursday, February 5th. TD Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $155.80.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.